The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).
This is an "open label" study which means there is no placebo group. Each subject enrolled into the study will receive AVP-923.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
600
emotional control
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Barrow Neurological Institute
Phoenix, Arizona, United States
Center for Neurologic Study
La Jolla, California, United States
UCLA School of Medicine
Los Angeles, California, United States
UCSF
San Francisco, California, United States
Research Center for Clinical Studies, Inc.
Darien, Connecticut, United States
George Washington University Medical Faculty Assoc.
Washington D.C., District of Columbia, United States
Neurological Associates
Fort Lauderdale, Florida, United States
University of Miami Dept. of Neurology
Miami, Florida, United States
Miami Jewish Home & Hospital for the Aged
Miami, Florida, United States
Allied Clinical Trials
Miami, Florida, United States
...and 29 more locations